PharmaVigilant Launches PaySite 2.0, A New Site Payment System
PharmaVigilant
today unveiled PaySite 2.0, a new Site Payment System that provides a complete dashboard to the sponsor, enabling them to program site payments based upon performance and individual site contracts. With PaySite, sponsors can determine payments made both graphically and within defined reports, and generate site letters defining the payouts and the criteria associated with the payment. Combined, this functionality streamlines the site payment process, improving the relationship between the sponsor and the site.
PaySite has no limitations regarding combinations; complex compensation programs can be easily defined and implemented in any currency. Information can be exported in sponsors’ accounting systems to further streamline the payment process.
“One of the keys to enhancing site/sponsor relationships is paying sites on time. As sponsors’ accounting processes elongate in complexity and time, site payments get extended, creating stress on the relationship,” said James DeSanti, founder and chief executive officer, PharmaVigilant. “PaySite reduces the time upfront by creating payment reports on-demand, or with manual overrides when required.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
